Bioagelabs
BioAge Labs is a clinical-stage biotechnology company (NASDAQ: BIOA) based in Emeryville, California, that harnesses the biology of human aging to develop new therapies for metabolic and cardiometabolic disease. Its AI-driven discovery platform mines proprietary multi-omics data from large, longitudinal human aging cohorts to identify the molecular pathways that drive age-related disease, then advances small-molecule and biologic drug candidates against those targets. The clinical pipeline centers on BGE-102, an oral NLRP3 inflammasome inhibitor aimed at cardiovascular inflammation, and next-generation APJ (apelin receptor) agonists developed as exercise mimetics for obesity and cardiometabolic conditions. This profile was surfaced as a portfolio company of Felicis and enriched into the API Evangelist network; BioAge is a therapeutics developer and does not currently publish a public developer API, SDK, or documentation surface.
Bioagelabs is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Longevity, and Aging.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Commercial 1
Pricing, plans, and the legal terms of use
Company 1
The organization behind the API